NASDAQ : XTLB
XTL Biopharmaceuticals Ltd. — Financial statements
Healthcare · Biotechnology · Israel
Last price 1.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 1.44M | 1.44M | 759.00K | 734.00K | 850.00K | 1.00M |
| Research & Development | 28.00K | 28.00K | 16.00K | 31.00K | 30.00K | 30.00K |
| Operating Expenses | 1.47M | 1.47M | 775.00K | 765.00K | 880.00K | 1.03M |
| Operating Income | -1.47M | -1.47M | -775.00K | -765.00K | -880.00K | -1.03M |
| Interest Expense | -7.00K | -7.00K | -28.00K | |||
| Interest & Investment Income | 60.00K | 60.00K | 34.00K | 41.00K | 36.00K | 8.00K |
| Currency Exchange Gain (Loss) | -152.00K | -152.00K | -26.00K | -32.00K | -16.00K | 13.00K |
| Other Non Operating Income (Expenses) | -79.00K | -79.00K | -58.00K | -4.00K | -11.00K | 698.00K |
| EBT Excluding Unusual Items | -1.64M | -1.64M | -853.00K | -760.00K | -871.00K | -312.00K |
| Gain (Loss) on Sale of Investments | 1.11M | 1.11M | 1.09M | -1.02M | -477.00K | 747.00K |
| Asset Writedown | -223.00K | -223.00K | ||||
| Pretax Income | -759.00K | -759.00K | 240.00K | -1.78M | -1.35M | 435.00K |
| Earnings From Continuing Operations | -759.00K | -759.00K | 240.00K | -1.78M | -1.35M | 435.00K |
| Earnings From Discontinued Operations | -6.21M | -6.21M | -1.27M | |||
| Net Income | -6.97M | -6.97M | -1.03M | -1.78M | -1.35M | 435.00K |
| Net Income to Common | -6.97M | -6.97M | -1.03M | -1.78M | -1.35M | 435.00K |
| Shares Outstanding (Basic) | 896.17M | 896.17M | 673.04M | 544.91M | 544.91M | 532.00M |
| Shares Outstanding (Diluted) | 896.17M | 896.17M | 673.04M | 544.91M | 544.91M | 615.55M |
| EPS (Basic) | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | 0.00 |
| EPS (Diluted) | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | 0.00 |
| Free Cash Flow | -1.02M | -1.02M | -1.67M | -707.00K | -901.00K | -1.05M |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| EBITDA | -1.27M | -1.27M | -576.00K | -764.00K | -879.00K | -1.03M |
| D&A For EBITDA | 199.00K | 199.00K | 199.00K | 1.00K | 1.00K | 1.00K |
| EBIT | -1.47M | -1.47M | -775.00K | -765.00K | -880.00K | -1.03M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 76.00K | 76.00K | 371.00K | 1.40M | 2.09M | 2.97M |
| Trading Asset Securities | 772.00K | 605.00K | 1.63M | 3.16M | ||
| Cash & Short-Term Investments | 76.00K | 76.00K | 1.14M | 2.01M | 3.72M | 6.13M |
| Accounts Receivable | 99.00K | |||||
| Receivables | 99.00K | |||||
| Prepaid Expenses | 51.00K | 29.00K | 71.00K | 94.00K | ||
| Other Current Assets | 90.00K | 90.00K | 47.00K | 11.00K | 14.00K | 16.00K |
| Total Current Assets | 166.00K | 166.00K | 1.34M | 2.05M | 3.81M | 6.24M |
| Property, Plant & Equipment | 187.00K | 1.00K | ||||
| Goodwill | 3.19M | |||||
| Other Intangible Assets | 3.82M | 380.00K | 380.00K | 380.00K | ||
| Other Long-Term Assets | 14.00K | |||||
| Total Assets | 166.00K | 166.00K | 8.55M | 2.43M | 4.19M | 6.62M |
| Accounts Payable | 20.00K | 20.00K | 227.00K | 1.00K | 2.00K | 2.00K |
| Accrued Expenses | 131.00K | 131.00K | 545.00K | 205.00K | 185.00K | 229.00K |
| Short-Term Debt | 138.00K | |||||
| Current Unearned Revenue | 18.00K | |||||
| Other Current Liabilities | 269.00K | 269.00K | 1.28M | |||
| Total Current Liabilities | 420.00K | 420.00K | 2.21M | 206.00K | 187.00K | 231.00K |
| Long-Term Deferred Tax Liabilities | 219.00K | |||||
| Other Long-Term Liabilities | 689.00K | 1.05M | ||||
| Total Liabilities | 420.00K | 420.00K | 3.12M | 206.00K | 187.00K | 1.28M |
| Common Stock | 25.14M | 25.14M | 23.14M | 14.12M | 14.12M | 14.12M |
| Additional Paid-In Capital | 140.22M | 140.22M | 141.29M | 146.33M | 146.33M | 146.33M |
| Retained Earnings | -165.63M | -165.63M | -159.01M | -158.25M | -156.47M | -155.13M |
| Comprehensive Income & Other | 20.00K | 20.00K | 20.00K | 20.00K | 20.00K | 20.00K |
| Shareholders' Equity | -254.00K | -254.00K | 5.43M | 2.22M | 4.00M | 5.33M |
| Total Liabilities & Equity | 166.00K | 166.00K | 8.55M | 2.43M | 4.19M | 6.62M |
| Total Debt | 138.00K | |||||
| Net Cash (Debt) | 76.00K | 76.00K | 1.00M | 2.01M | 3.72M | 6.13M |
| Net Cash Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Filing Date Shares Outstanding | 982.99M | 982.99M | 881.39M | 544.91M | 544.91M | 544.91M |
| Total Common Shares Outstanding | 946.24M | 946.24M | 881.39M | 544.91M | 544.91M | 544.91M |
| Working Capital | -254.00K | -254.00K | -867.00K | 1.84M | 3.62M | 6.01M |
| Book Value Per Share | -0.00 | -0.00 | 0.01 | 0.00 | 0.01 | 0.01 |
| Tangible Book Value | -254.00K | -254.00K | -1.57M | 1.84M | 3.62M | 4.95M |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | 0.00 | 0.01 | 0.01 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -6.97M | -6.97M | -1.03M | -1.78M | -1.35M | 435.00K |
| Depreciation & Amortization | 199.00K | 1.00K | 1.00K | |||
| Loss (Gain) From Sale of Assets | 6.21M | 6.21M | ||||
| Asset Writedown & Restructuring Costs | 223.00K | 223.00K | ||||
| Loss (Gain) From Sale of Investments | -5.00K | -5.00K | -167.00K | 1.02M | 1.53M | -747.00K |
| Stock-Based Compensation | 346.00K | 346.00K | 264.00K | 3.00K | 14.00K | 37.00K |
| Provision & Write-off of Bad Debts | 308.00K | 308.00K | ||||
| Other Operating Activities | -1.14M | -1.14M | -1.08M | -14.00K | -1.08M | -721.00K |
| Change in Accounts Receivable | 157.00K | 157.00K | 39.00K | |||
| Change in Accounts Payable | -187.00K | -187.00K | 208.00K | 19.00K | -44.00K | -23.00K |
| Change in Other Net Operating Assets | 28.00K | 28.00K | -58.00K | 45.00K | 25.00K | -31.00K |
| Operating Cash Flow | -1.02M | -1.02M | -1.62M | -707.00K | -901.00K | -1.05M |
| Capital Expenditures | -54.00K | |||||
| Cash Acquisitions | -410.00K | |||||
| Investment in Securities | 777.00K | 777.00K | -14.00K | |||
| Other Investing Activities | -5.00K | -5.00K | 34.00K | 41.00K | 36.00K | 8.00K |
| Investing Cash Flow | 522.00K | 522.00K | -844.00K | 41.00K | 36.00K | 8.00K |
| Long-Term Debt Issued | 208.00K | 208.00K | ||||
| Long-Term Debt Repaid | -13.00K | |||||
| Net Debt Issued (Repaid) | 208.00K | 208.00K | -13.00K | |||
| Issuance of Common Stock | 1.46M | 385.00K | ||||
| Financing Cash Flow | 208.00K | 208.00K | 1.45M | 385.00K | ||
| Foreign Exchange Rate Adjustments | -15.00K | -27.00K | -10.00K | -6.00K | ||
| Net Cash Flow | -295.00K | -295.00K | -1.03M | -693.00K | -875.00K | -662.00K |
| Free Cash Flow | -1.02M | -1.02M | -1.67M | -707.00K | -901.00K | -1.05M |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Levered Free Cash Flow | -2.12M | -2.12M | 1.61M | -411.12K | -554.00K | -660.38K |
| Unlevered Free Cash Flow | -2.11M | -2.11M | 1.63M | -411.12K | -554.00K | -660.38K |
| Change in Working Capital | -2.00K | -2.00K | 189.00K | 64.00K | -19.00K | -54.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 5.90M | 7.12M | 22.38M | 5.30M | 6.35M | 14.97M |
| Enterprise Value | 5.82M | 6.94M | 20.63M | 2.96M | 1.91M | 11.85M |
| Last Close Price | 1.61 | 2.32 | 8.10 | 4.04 | 4.84 | 11.08 |
| PE Ratio | 34.41 | |||||
| PB Ratio | -28.05 | 4.12 | 2.38 | 1.59 | 2.81 | |
| P/TBV Ratio | 2.88 | 1.76 | 3.02 | |||
| Debt / Equity Ratio | 0.03 | |||||
| Net Debt / Equity Ratio | 0.30 | 0.30 | -0.18 | -0.90 | -0.93 | -1.15 |
| Net Debt / EBITDA Ratio | 0.06 | 0.06 | 1.75 | 2.63 | 4.23 | 5.95 |
| Net Debt / FCF Ratio | 0.07 | 0.07 | 0.60 | 2.84 | 4.13 | 5.84 |
| Quick Ratio | 0.18 | 0.18 | 0.56 | 9.74 | 19.90 | 26.52 |
| Current Ratio | 0.40 | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 |
| Return on Equity (ROE) | -29.30% | -29.30% | 6.27% | -57.31% | -28.89% | 9.73% |
| Return on Assets (ROA) | -21.01% | -21.01% | -8.83% | -14.46% | -10.18% | -9.82% |
| Return on Capital Employed (ROCE) | 576.80% | 576.80% | -12.20% | -34.50% | -22.00% | -16.10% |
| Earnings Yield | -198.10% | -97.83% | -4.59% | -33.65% | -21.22% | 2.91% |
| FCF Yield | -17.38% | -14.39% | -7.47% | -13.35% | -14.18% | -7.01% |
| Buyback Yield / Dilution | -52.32% | -33.15% | -23.52% | 0.00% | 11.48% | -19.71% |